Despite the development of coronary intervention techniques and advances in medication, acute myocardial infarction (AMI) remains the main cause of death from coronary artery disease [1]. Accumulating evidence from clinical trials shows that AMI has a great impact on cardiac remodeling and heart failure (HF), which impose a heavy economic burden [2,3]. According to Swede Heart Registration, HF occurred in 13–31% of patients over 1 year after AMI [1]. In order to improve the prognosis of high-risk AMI population, it is urgent to optimize the management measures.
